The initiation of coverage by Stifel with a Buy rating and a specific price target of $8 directly impacts Summit Therapeutics by potentially increasing investor confidence and demand for SMMT shares. This positive analyst rating serves as a strong endorsement of the company's value and prospects, likely leading to a short-term increase in stock price.